Independent Research on Mutual Funds, Stocks & IPOs for Indian Investors

Symbiotec Pharmalab Limited, based in Indore, Madhya Pradesh, operates through three business verticals: API products (96.07% of FY26 revenue), CDMO services and complex injectables. Manufacturing platform with aggregate chemical synthesis capacity of 584.67 MT, fermentation capacity of 700 KL and complex injectable capacity of 20 million vials annually. Serves 200+ customers across 40+ countries including US, Europe and Asia. Revenue Rs 872.26 Cr (2026) vs Rs 755.98 Cr (2025); PAT Rs 109.90 Cr vs Rs 96.79 Cr. Issue: fresh Rs 150 Cr + OFS of 1.63 Cr shares by promoters and investors including Satwani Holdings LLP. Final subscription: 71.26x overall. Anchor book raised Rs 526.19 Cr on Aug 21. Listed Sep 1, 2026: NSE Rs 988 (flat), BSE Rs 978.20 (-0.99%); closed Rs 1,095.95 (+10.93%).